Actively Recruiting
Acetazolamide Versus Dapagliflozin in Acute Decompensated Heart Failure Patients
Led by Helwan University · Updated on 2024-08-05
60
Participants Needed
1
Research Sites
53 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The goal of this clinical trial is to compare the effectiveness of acetazolamide versus dapagliflozin as an add-on in treating acute decompensated heart failure (ADHF) in adult patients with clinical signs of volume overload requiring intravenous loop diuretics. It will also assess the safety of these drugs when added to standard care. The main questions it aims to answer are: * Does acetazolamide or dapagliflozin lead to a greater reduction in N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels? * Which drug results in better loop diuretic efficiency, as measured by weight loss per 40 mg of intravenous furosemide or equivalent? We will compare acetazolamide to dapagliflozin, both added to standard intravenous loop diuretic therapy, to see which is more effective in decongesting patients with ADHF. Participants will: * Take either acetazolamide or dapagliflozin orally every day for 3 days * Receive intravenous loop diuretics as part of standard care * Undergo regular assessments of heart failure symptoms, weight, and laboratory tests * Be followed up until hospital discharge and for 30 days after starting the study
CONDITIONS
Official Title
Acetazolamide Versus Dapagliflozin in Acute Decompensated Heart Failure Patients
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Male or female patients aged 18 years or older
- Hospital admission with clinical diagnosis of decompensated heart failure and at least one sign of fluid overload (edema, ascites confirmed by echography, or pleural effusion confirmed by chest X-ray or echography)
- Left ventricular ejection fraction (LVEF) assessed by imaging within 12 months before enrollment
You will not qualify if you...
- Currently receiving acetazolamide maintenance therapy
- Taken an SGLT2 inhibitor within 48 hours before randomization
- Estimated glomerular filtration rate (eGFR) below 20 mL/min/1.73 m2
- Use of any non-protocol defined diuretics during the study treatment phase except mineralocorticoid receptor antagonists
- Thiazides, metolazone, indapamide, and amiloride must be stopped upon study inclusion
- If on a combination drug including a thiazide-type diuretic, the thiazide component must be stopped
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Critical Care Medicine Department - Cairo University Hospitals.
Cairo, Egypt
Actively Recruiting
Research Team
N
Nouran Mo Anwar, Bachelor
CONTACT
M
Mahmoud I Mostafa, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here